The cancer-focused antibody developer has secured $58.5m in a US flotation that involved existing investors Celgene and Eli Lilly buying more than $7m of shares.
Canada-based biopharmaceutical company Zymeworks has raised $58.5m in an initial public offering that gave exits to pharmaceutical firms Celgene, Eli Lilly and EMS.
The company issued 4.5 million shares on the New York Stock Exchange priced at $13.00 each, at the low end of the $13 to $16 range it had previously set, and is seeking approval to list additional shares on the Toronto Stock Exchange in Canada.
Some of the company’s existing investors, including Eli Lilly and Celgene,…
